Download Files:
Products Details
Product Description
– Cemdisiran, terminal sugar modification- is an investigational N-acetylgalactosamine-conjugated RNAi agent. Cemdisiran, a siRNA-targeting C5 mRNA, suppresses liver production of complement component C5[1].
Web ID
– HY-147077
Shipping
– Room temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C78H140N11O34P
References
– [1]Kishor Devalaraja-Narashimha ,et al. Pharmacokinetics and pharmacodynamics of pozelimab alone or in combination with cemdisiran in non-human primates. PLoS One. 2022 Jun 16;17(6):e0269749.|[2]Ellen S Smith, et al. Clinical Applications of Short Non-Coding RNA-Based Therapies in the Era of Precision Medicine. Cancers (Basel). 2022 Mar 21;14(6):1588.
CAS Number
– 1436858-07-9
Molecular Weight
– 1806.97
SMILES
– CC(N[C@H]([C@H]([C@H]([C@H](O1)CO)O)O)[C@@H]1OCCCCC(NCCCNC(CCOCC(COCCC(NCCCNC(CCCCO[C@H]2[C@@H]([C@H]([C@H]([C@H](O2)CO)O)O)NC(C)=O)=O)=O)(NC(CCCCCCCCCCC(N3[C@@H](C[C@H](C3)O)COP(O)(O)=O)=O)=O)COCCC(NCCCNC(CCCCO[C@H]4[C@@H]([C@H]([C@H]([C@H](O4)CO)O)O)NC(C)=O)=O)=O)=O)=O)=O
Clinical Information
– No Development Reported
Research Area
– Inflammation/Immunology
Solubility
– 10 mM in DMSO
Target
– Complement System
Pathway
– Immunology/Inflammation
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
